Maren Leifheit-Nestler1, Alexander Grabner2, Laura Hermann1, Beatrice Richter1, Karin Schmitz3, Dagmar-Christiane Fischer3, Christopher Yanucil2,4, Christian Faul2,4, Dieter Haffner1. 1. Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany. 2. Department of Medicine, Katz Family Drug Discovery Center and Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL, USA. 3. Department of Pediatrics, University Hospital Rostock, Rostock, Germany. 4. Department of Cell Biology and Anatomy, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA.
Abstract
BACKGROUND: Vitamin D deficiency and excess of circulating fibroblast growth factor 23 (FGF23) contribute to cardiovascular mortality in patients with chronic kidney disease (CKD). FGF23 activates FGF receptor 4 and (FGFR4) calcineurin/nuclear factor of activated T cells (NFAT) signaling in cardiac myocytes, thereby causing left ventricular hypertrophy (LVH). Here, we determined if 1,25-dihydroxyvitamin D (calcitriol) inhibits FGF23-induced cardiac signaling and LVH. METHODS: 5/6 nephrectomized (5/6 Nx) rats were treated with different doses of calcitriol for 4 or 10 weeks and cardiac expression of FGF23/FGFR4 and activation of calcineurin/NFAT as well as LVH were analyzed. FGFR4 activation and hypertrophic cell growth were studied in cultured cardiac myocytes that were co-treated with FGF23 and calcitriol. RESULTS: In 5/6Nx rats with LVH, we detected elevated FGF23 expression in bone and myocardium, increased cardiac expression of FGFR4 and elevated cardiac activation of calcineurin/NFAT signaling. Cardiac expression levels of FGF23 and FGFR4 significantly correlated with the presence of LVH in uremic rats. Treatment with calcitriol reduced LVH as well as cardiac FGFR4 expression and calcineurin/NFAT activation. Bone and cardiac FGF23 expression were further stimulated by calcitriol in a dose-dependent manner, but levels of intact cardiac FGF23 protein were suppressed by high-dose calcitriol. In cultured cardiac myocytes, co-treatment with calcitriol blocked FGF23-induced activation of FGFR4 and hypertrophic cell growth. CONCLUSIONS: Our data suggest that in CKD, cardioprotective effects of calcitriol stem from its inhibitory actions on the cardiac FGF23/FGFR4 system, and based on their counterbalancing effects on cardiac myocytes, high FGF23 and low calcitriol synergistically contribute to cardiac hypertrophy.
BACKGROUND: Vitamin D deficiency and excess of circulating fibroblast growth factor 23 (FGF23) contribute to cardiovascular mortality in patients with chronic kidney disease (CKD). FGF23 activates FGF receptor 4 and (FGFR4) calcineurin/nuclear factor of activated T cells (NFAT) signaling in cardiac myocytes, thereby causing left ventricular hypertrophy (LVH). Here, we determined if 1,25-dihydroxyvitamin D (calcitriol) inhibits FGF23-induced cardiac signaling and LVH. METHODS: 5/6 nephrectomized (5/6 Nx) rats were treated with different doses of calcitriol for 4 or 10 weeks and cardiac expression of FGF23/FGFR4 and activation of calcineurin/NFAT as well as LVH were analyzed. FGFR4 activation and hypertrophic cell growth were studied in cultured cardiac myocytes that were co-treated with FGF23 and calcitriol. RESULTS: In 5/6Nx rats with LVH, we detected elevated FGF23 expression in bone and myocardium, increased cardiac expression of FGFR4 and elevated cardiac activation of calcineurin/NFAT signaling. Cardiac expression levels of FGF23 and FGFR4 significantly correlated with the presence of LVH in uremic rats. Treatment with calcitriol reduced LVH as well as cardiac FGFR4 expression and calcineurin/NFAT activation. Bone and cardiac FGF23 expression were further stimulated by calcitriol in a dose-dependent manner, but levels of intact cardiac FGF23 protein were suppressed by high-dose calcitriol. In cultured cardiac myocytes, co-treatment with calcitriol blocked FGF23-induced activation of FGFR4 and hypertrophic cell growth. CONCLUSIONS: Our data suggest that in CKD, cardioprotective effects of calcitriol stem from its inhibitory actions on the cardiac FGF23/FGFR4 system, and based on their counterbalancing effects on cardiac myocytes, high FGF23 and low calcitriol synergistically contribute to cardiac hypertrophy.
Authors: Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards Journal: J Clin Invest Date: 2012-06-25 Impact factor: 14.808
Authors: Maren Leifheit-Nestler; Robert Große Siemer; Kathrin Flasbart; Beatrice Richter; Felix Kirchhoff; Wolfgang H Ziegler; Michael Klintschar; Jan U Becker; Andreas Erbersdobler; Christoph Aufricht; Tomas Seeman; Dagmar-Christiane Fischer; Christian Faul; Dieter Haffner Journal: Nephrol Dial Transplant Date: 2015-12-17 Impact factor: 5.992
Authors: Songcang Chen; Christopher S Law; Christopher L Grigsby; Keith Olsen; Ting-Ting Hong; Yan Zhang; Yerem Yeghiazarians; David G Gardner Journal: Circulation Date: 2011-09-26 Impact factor: 29.690
Authors: Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Carol A Haussler; David Hsieh; Jui-Cheng Hsieh; Peter W Jurutka Journal: Calcif Tissue Int Date: 2012-07-11 Impact factor: 4.333
Authors: Chad D Touchberry; Troy M Green; Vladimir Tchikrizov; Jaimee E Mannix; Tiffany F Mao; Brandon W Carney; Magdy Girgis; Robert J Vincent; Lori A Wetmore; Buddhadeb Dawn; Lynda F Bonewald; Jason R Stubbs; Michael J Wacker Journal: Am J Physiol Endocrinol Metab Date: 2013-02-26 Impact factor: 4.310
Authors: Jonah M Graves; Julian A Vallejo; Chelsea S Hamill; Derek Wang; Rohan Ahuja; Shaan Patel; Christian Faul; Michael J Wacker Journal: Am J Physiol Heart Circ Physiol Date: 2021-04-30 Impact factor: 5.125
Authors: Ian Moench; Karpagam Aravindhan; Joanne Kuziw; Christine G Schnackenberg; Robert N Willette; John R Toomey; Gregory J Gatto Journal: J Endocr Soc Date: 2021-04-08